Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Externally applied pharmaceutical composition for treating skin fungal infection

A technology of topical medicine and skin fungus, which is applied in the field of medicine, can solve problems affecting the quality of life of patients, and achieve the effects of relieving skin burning sensation, shortening the anti-itching time, and enhancing antifungal activity

Active Publication Date: 2013-11-13
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, since terbinafine hydrochloride and butenafine hydrochloride fundamentally treat local skin fungal infections by killing or inhibiting fungi, this will inevitably relieve symptoms such as local skin itching, skin flushing or redness, especially pruritus symptoms take a long time
Therefore, when the patient's itching is unbearable, the itching cannot be relieved quickly, which affects the quality of life of the patient to a certain extent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Externally applied pharmaceutical composition for treating skin fungal infection
  • Externally applied pharmaceutical composition for treating skin fungal infection
  • Externally applied pharmaceutical composition for treating skin fungal infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Embodiment 1 gel

[0056] Butenafine Hydrochloride 10g

[0057] Miconazole Nitrate 2.5g

[0058] Loratadine 2.5g

[0059] 1,2-propanediol 100g

[0060] Glycerol 50g

[0061] Carbopol 940 10g

[0062] Polysorbate-80 2g

[0063] Sodium hydroxide 4g

[0064] Ethylparaben 1g

[0065] Distilled water up to 1000g

[0066] Preparation process: Dissolve butenafine hydrochloride, miconazole nitrate and loratadine in 1,2-propanediol, then add appropriate amount of distilled water and glycerin, then mix carbopol 940 with polysorbate-80 and 300ml of distilled water, mix well, dissolve sodium hydroxide in 100ml of distilled water, add supernatant and mix well, then dissolve ethylparaben in ethanol, add gradually and stir well, to obtain transparent gel.

Embodiment 2

[0067] Embodiment 2 gel

[0068] Butenafine Hydrochloride 10g

[0069] Cetirizine Hydrochloride 5g

[0070] 1,2-propanediol 80g

[0071] Glycerol 100g

[0072] Carbopol 940 8g

[0073] Polysorbate 80 2g

[0074] Ethylparaben 1g

[0075] Distilled water up to 1000g

[0076] Triethanolamine to adjust pH to 6.0

[0077] Preparation process: Dissolve butenafine hydrochloride and cetirizine hydrochloride in 1,2-propanediol, then add appropriate amount of distilled water and glycerol, then mix carbopol 940 with polysorbate-80 and 300ml distilled water Mix evenly, adjust the pH value to 6.0 with triethanolamine, then dissolve ethylparaben in ethanol, add gradually and stir evenly, add distilled water to 1000g, and obtain a transparent gel.

Embodiment 3

[0078] Embodiment 3 gel

[0079] Terbinafine Hydrochloride 10g

[0080] Cetirizine Hydrochloride 10g

[0081] 1,2-propanediol 100g

[0082] Glycerol 50g

[0083] Carbopol 940 10g

[0084] Polysorbate 80 2g

[0085] Ethylparaben 1g

[0086] Distilled water up to 1000g

[0087] Adjust pH to 7.0 with triethanolamine

[0088] The preparation process is the same as in Example 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an externally applied pharmaceutical composition containing a squalene epoxidase inhibitor and an H1 receptor blocker, which aims at overcoming the defect that the antipruritic effect of the squalene epoxidase inhibitor is non-obvious when being used for treating fungal infection. The pharmaceutical composition provided by the invention has the characteristics of killing fungi and realizing synergistic anti-inflammation and synergistic antipruritic effect, and can significantly improve the symptoms of superficial skin fungal infection.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to an external pharmaceutical composition for treating skin fungus infection. Background technique [0002] Superficial skin fungal infectious diseases account for a high proportion of skin diseases, are generally easy to relapse, and are difficult to cure, and belong to one of the intractable skin diseases. Clinically common skin fungal infectious diseases include tinea manuum, tinea pedis, jock itch, tinea corporis, tinea capitis, etc. The symptoms are mainly manifested in local skin moist flushing, erosion, maceration and whitish or small blisters, unbearable itching of the skin, erysipelas and lymphangitis often caused by secondary infection after scratching, easy keratosis and desquamation after drying, chapped. Can be contagious, easy to relapse. The main causes of skin fungal infections are Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton gypsum, Trichophyton violaceu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4545A61K31/137A61K31/495A61K31/445A61K31/496A61K31/4174A61K31/4196A61P31/10A61P17/00A61P17/04A61P29/00
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com